When Should Pharmacists Start Dual Antihypertensive Therapy?

At the New England Institute of Ambulatory Care Pharmacists (NEIAP) 2026 Annual Forum in Boston, Massachusetts, Anthony Ishak, PharmD, clinical pharmacist at Massachusetts General Hospital in Boston, Massachusetts, discussed with Pharmacy Times how pharmacists can act as primary clinical decision-makers when initiating and intensifying antihypertensive therapy.

Ishak focused on risk-guided treatment selection, the current place of dual versus triple single-pill combinations, and the design of pharmacist-led titration protocols that counter therapeutic inertia. He explained that the PREVENT risk estimator is most useful when deciding on dual therapy in patients with stage 2 hypertension, where combination therapy is typically required. According to Ishak, the score helps quantify a patient's risk and, in turn, informs how aggressively to lower blood pressure and how strong a dose to consider.

Shifting to product selection, Ishak said that although a triple single-pill combination has recently been approved (telmisartan/amlodipine/indapamide; Widaplik, George Medicines), its trial exclusion criteria make it difficult to apply to many patients seen in practice. He noted that dual therapy is well studied and that multiple dual options have strong third-party payer coverage at usable doses, which supports getting patients to goal. For now, he positions dual combination products as the practical choice, with triple therapy worth watching as coverage broadens.

To overcome inertia, Ishak described pairing objective risk scores with patient-prioritized comorbidities—such as migraines or Raynaud’s—to choose agents that address more than blood pressure alone. He emphasized building a fixed process for agent selection and dose titration based on numbers and tolerance, arguing that a standardized protocol reduces hesitancy among clinicians and patients and reinforces the evidence that aggressive early treatment lowers risk and reaches goals faster.